Table 2.

Comparison of clinical parameters between the non-HCQ and HCQ groups

COVID-19 patients (N = 154)
Demographics	Non-HCQ N = 59 (%)	HCQ N = 95 (%)	p value
Gender
Male	36 (61.0)	51 (53.7)	0.372
Female	26 (39.0)	44 (46.3)
Age (years)	61 (22–89)	59 (21–90)	0.254
Systemic Arterial Hypertension	30 (50.8)	48 (50.5)	0.969
Type 2 diabetes mellitus	19 (32.2)	31 (32.6)	0.956
Obesity	7 (11.9)	17 (17.9)	0.316
COPD	2 (3.4)	4 (4.2)	0.798
Asthma	0	5 (5.3)	0.073
Kidney disease	6 (10.2)	7 (7.4)	0.543
Hepatic disease	0	3 (3.2)	0.168
Cardiopathy	6 (10.2)	7 (7.4)	0.543
Cancer	20 (33.9)	12 (12.6)	0.002
Autoimmune disease	2 (3.4)	4 (4.2)	0.798
Dyslipidemia	4 (6.8)	3 (3.2)	0.294
Neuro and psychiatric disorders	7 (11.9)	5 (5.3)	0.137
Smoking
Yes  Ex	3 (5.1) 7 (11.9)	7 (7.4) 4 (4.2)	0.183
Alcoholic
Yes  Ex	1 (1.7) 4 (6.8)	2 (2.1) 0	0.036
Comorbidities	55 (93.2)	81 (85.3)	0.135
Comorbidities ≥ 2	43 (78.2)	57 (70.4)	0.311
Pulmonary involvement > 50%	20 (42.6)	39 (55.7)	0.163
Pneumonia	55 (93.2)	94 (98.9)	0.071
ICU admission	41 (69.5)	76 (80.0)	0.138
Oseltamivir	33 (55.9)	85 (89.5)	< 0.001
Azithromycin	39 (66.1)	91 (95.8)	< 0.001
Corticosteroids	40 (67.8)	75 (78.9)	0.122
Heparin	52 (88.1)	94 (98.9)	0.005
Endotracheal Intubation	12 (20.3)	33 (34.7)	0.056
DVT	1 (1.7)	1 (1.1)	1.000

Comparison of categorical variables using the Chi-square test between non-HCQ and HCQ groups. ICU Intensive care unit, DVT Deep vein thrombosis, N number of individuals, % percentage